Javier G. Ros

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications

Relative Mutant Allele Frequency Role in ctDNA-Guided Anti-Epidermal Growth Factor Receptor Rechallenge in Metastatic Colorectal Cancer.

Relative Mutant Allele Frequency Role in ctDNA-Guided Anti-Epidermal Growth Factor Receptor Rechallenge in Metastatic Colorectal Cancer.

Journal: JCO precision oncology
Published: September 01, 2026

Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2-Amplified Metastatic Colorectal Cancer.

Rechallenge With Anti-Human Epidermal Growth Factor Receptor 2 Therapy Guided by Liquid Biopsy in HER2-Amplified Metastatic Colorectal Cancer.

Journal: JCO precision oncology
Published: July 29, 2026

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.

Journal: Genes
Published: March 10, 2026

Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.

Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.

Journal: The oncologist
Published: February 10, 2026

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients.

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients.

Journal: ESMO gastrointestinal oncology
Published: February 06, 2026

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations.

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations.

Journal: ESMO gastrointestinal oncology
Published: February 06, 2026

Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.

Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.

Journal: ESMO open
Published: December 23, 2025

Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer.

Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer.

Journal: Cancer treatment reviews
Published: October 05, 2025

Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies.

Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies.

Journal: Drugs
Published: September 08, 2025

New prognostic and predictive scoring systems for colorectal cancer liver metastases.

New prognostic and predictive scoring systems for colorectal cancer liver metastases.

Journal: ESMO open
Published: August 05, 2025

Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis.

Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis.

Journal: Annals of the rheumatic diseases
Published: July 13, 2025

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

Journal: ESMO open
Published: June 16, 2025
Showing 1-12 of 77

Last Updated: 09/26/2026